Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGSWW) Shares Outstanding (2020 - 2025)

GeneDx Holdings has reported Shares Outstanding over the past 6 years, most recently at $29.2 million for Q4 2025.

  • Quarterly results put Shares Outstanding at $29.2 million for Q4 2025, up 4.39% from a year ago — trailing twelve months through Dec 2025 was $29.2 million (up 4.39% YoY), and the annual figure for FY2025 was $29.2 million, up 4.39%.
  • Shares Outstanding for Q4 2025 was $29.2 million at GeneDx Holdings, up from $28.9 million in the prior quarter.
  • Over the last five years, Shares Outstanding for WGSWW hit a ceiling of $240.2 million in Q3 2021 and a floor of $748761.0 in Q1 2021.
  • Median Shares Outstanding over the past 5 years was $25.9 million (2023), compared with a mean of $30.9 million.
  • Biggest five-year swings in Shares Outstanding: soared 193701837.1% in 2021 and later plummeted 93.22% in 2023.
  • GeneDx Holdings' Shares Outstanding stood at $7.4 million in 2021, then soared by 60.11% to $11.8 million in 2022, then soared by 120.66% to $26.0 million in 2023, then rose by 7.84% to $28.0 million in 2024, then grew by 4.39% to $29.2 million in 2025.
  • The last three reported values for Shares Outstanding were $29.2 million (Q4 2025), $28.9 million (Q3 2025), and $28.7 million (Q2 2025) per Business Quant data.